FAQ: HeartBeam Inc.'s High-Fidelity At-Home Heart-Monitoring System
Summary
What is the HeartBeam System?
The HeartBeam System is a cable-free, high-fidelity ECG system developed by HeartBeam (NASDAQ: BEAT) that captures the heart’s electrical signals from three distinct directions and synthesizes them into a 12-lead ECG, enabling comprehensive arrhythmia assessment outside clinical settings.
Why is this system significant compared to traditional ECG systems?
Traditional 12-lead ECG systems have limitations including cumbersome setups requiring trained clinicians, time-consuming processes, multiple electrodes and wires, and confinement to clinical settings. The HeartBeam System addresses these challenges by being cable-free, user-friendly, portable, and enabling at-home monitoring.
How does the HeartBeam System work?
The system captures the heart’s electrical signals from three distinct directions and synthesizes these signals into a 12-lead ECG, providing comprehensive assessment of the heart’s electrical activity similar to traditional clinical systems but in a more convenient format.
When will the HeartBeam System be commercially available?
HeartBeam plans to initiate commercial launch upon FDA clearance of its 12-lead ECG synthesis software, which is anticipated later this year.
What are the main benefits of this system for patients?
The system provides patients with the ability to monitor their heart health conveniently and accurately outside clinical settings, aligning with the growing trend toward remote patient monitoring and telemedicine while emphasizing user friendliness and portability.
Who developed this technology?
The technology was developed by HeartBeam Inc. (NASDAQ: BEAT), a company addressing challenges in cardiac diagnostics through innovative ECG solutions.
Where can I find more information about HeartBeam and updates on this technology?
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT, and more detailed information can be found at BioMedWire.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 204825